Clinical trials
Chronic Lymphocytic Leukemia clinical trials
Below are recruiting chronic lymphocytic leukemia clinical trials, each written for real people, not researchers. We’re tracking 203 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05131022RecruitingPhase 1
Study of NX-5948 for relapsed B-cell blood cancers
This Phase 1 study tests NX-5948 in adults whose B-cell cancers have come back or did not respond to prior treatment. It aims to find a safe dose and see how well the treatment works in different types of B-cell malignancies.
Duarte, CaliforniaAges 18 years+ - NCT05147467RecruitingPhase 2
Trial of APG-2575 for returning or resistant CLL/SLL
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT05168930RecruitingPhase 2
Zanubrutinib plus venetoclax for relapsed CLL or SLL
This Phase 2 study tests how well zanubrutinib (a targeted pill) combined with venetoclax (another targeted pill) works for adults with CLL/SLL that came back or progressed after prior treatment. It may help by stopping cancer cells through two different pathways, aiming to shrink disease and improve blood counts.
Scarborough, MaineAges 18 years+ - NCT05183854RecruitingPhase 2
Vaccine study for CLL patients to prevent pneumococcal infections
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
Salt Lake City, UtahAges 18 years+ - NCT05246345Recruiting
Study for chronic lymphocytic leukemia after venetoclax failure
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
AmiensAges 18 years+ - NCT05254743RecruitingPhase 3
Pirtobrutinib versus ibrutinib for CLL or SLL
This Phase 3 trial compares two oral medicines—pirtobrutinib and ibrutinib—in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who need treatment. It’s designed to see which drug works better and is easier to take, especially for people with a specific genetic change in the cancer (17p deletion).
Anaheim, CaliforniaAges 18 years+ - NCT05326308Recruiting
Zanubrutinib treatment in several blood cancers
This non-interventional study looks at outcomes for people with certain slow-growing blood cancers who are treated with zanubrutinib, with specific add-on use of obinutuzumab for follicular lymphoma. It may help doctors understand how this treatment is working in real-world care across several cancer types.
SalzburgAges 18 years+ - NCT05336812RecruitingPhase 2
Acalabrutinib with venetoclax or obinutuzumab for untreated CLL
This Phase 2 trial studies how well acalabrutinib works when combined with either venetoclax or obinutuzumab in people with untreated chronic lymphocytic leukemia (CLL). It aims to improve disease control while checking safety and tolerability.
Columbus, OhioAges 18 years+ - NCT05388006RecruitingPhase 2
Testing three medicines for Richter transformation in CLL/SLL
This Phase 2 trial studies acalabrutinib, venetoclax, and durvalumab together for Richter transformation (a more aggressive lymphoma) that developed from CLL or SLL. The goal is to improve how well treatment works and how long people can respond.
Palo Alto, CaliforniaAges 18 years+ - NCT05417165RecruitingPhase 2
Pneumococcal vaccine plan for CLL or SLL patients
This Phase 2 study tests a specific plan for giving a pneumococcal vaccine in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It may help improve protection against pneumococcal infections in patients who have not started CLL/SLL treatment yet.
Columbus, OhioAges 18 years+ - NCT05418088RecruitingPhase 1
CAR T-cell therapy for hard-to-treat B-cell cancers
This Phase 1 study tests lab-made immune cells (CAR T-cells) that target CD19, CD20, and/or CD22 in people with certain relapsed or refractory B-cell cancers. It may help by attacking cancer cells that still carry these targets, but eligibility is very specific and includes prior treatments and health/lab requirements.
Columbus, OhioAges 2 years+ - NCT05512390RecruitingPhase 1
Test drug ABBV-319 in B-cell blood cancers
This Phase 1 trial studies ABBV-319 given by vein to see what side effects it causes and how the cancer activity changes in certain B-cell blood cancers. It may help people with relapsed or treatment-resistant disease by exploring new treatment options and better understanding how the drug moves through the body.
Tucson, ArizonaAges 18 years+ - NCT05557695Recruiting
Acalabrutinib patient study for early access CLL in the UK
This observational study follows adults in the UK who started acalabrutinib through an early access program for chronic lymphocytic leukemia (CLL). It aims to learn what happens in real-world care after starting the medicine.
AylesburyAges 18–130 - NCT05602363RecruitingPhase 1
Docirbrutinib for CLL or lymphoma after prior treatments
This Phase 1 study tests docirbrutinib, a targeted pill treatment, in people with CLL/SLL or certain other B-cell lymphomas that have come back or didn’t respond to earlier therapy. The goal is to see whether it’s safe and whether it can control the disease after standard treatments have failed.
Orange, CaliforniaAges 18 years+ - NCT05643235Recruiting
Loop monitor to watch heart rhythms when starting a BTK inhibitor
This study checks how often abnormal heart rhythms happen when you start a BTK inhibitor (used for certain blood cancers). It uses a small implanted heart monitor to record your rhythm continuously before and after starting the medication, so doctors can detect and manage problems early.
New Hyde Park, New YorkAges 18 years+ - NCT05643742RecruitingPhase 1/Phase 2
Study of CTX112 for B-cell cancers that came back or did not respond
This Phase 1/2 study tests how safe and effective CTX112 is for adults whose B-cell cancer has returned or is not responding to treatment. It aims to see whether CTX112 can control the cancer while monitoring side effects closely.
Westwood, KansasAges 18 years+ - NCT05694312RecruitingPhase 2
Ibrutinib for anemia caused by immune destruction in CLL/SLL
This Phase 2 trial tests ibrutinib, a prescription medicine, to treat active autoimmune hemolytic anemia (AIHA) in people with CLL/SLL or a CLL-like condition. It may help reduce anemia when steroids don’t work well, don’t last, or are needed too long.
FlorenceAges 18 years+ - NCT05705570RecruitingPhase 1
CAR-T for CD19-positive relapsed or resistant blood cancers
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
São Paulo, São PauloAges 2–70 - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05876923Recruiting
Exercise study for immune changes in indolent blood cancers
This study looks at how an exercise program may change parts of the immune system in people with slow-growing (indolent) non-Hodgkin lymphoma or chronic lymphocytic leukemia (CLL/SLL). It may help researchers understand which immune changes could be important for your condition.
Scottsdale, ArizonaAges 18–80 - NCT05943496RecruitingPhase 1
Tafasitamab plus acalabrutinib and obinutuzumab for untreated CLL/SLL
This Phase 1 study tests a new combination of medicines to treat people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has not been treated before and needs therapy. It aims to shrink the disease and control it safely in this early testing stage.
Portland, OregonAges 18 years+ - NCT05959694RecruitingPhase 1/Phase 2
Study drug TQB3909 for CLL/SLL that keeps coming back
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
Anqing, AnhuiAges 18–75 - NCT05963217RecruitingPhase 1
Study of a patient’s own CAR T cells for CD19 cancers
This Phase 1 study tests a personalized form of CAR T cell treatment made from your own immune cells to fight certain CD19-positive blood cancers that have returned or not responded to prior treatment. It mainly looks at safety and how well the treatment can work.
Toronto, OntarioAges 18 years+
Hear when a new Chronic Lymphocytic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for chronic lymphocytic leukemia?
- Yes. Clin2 currently lists 203 recruiting chronic lymphocytic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a chronic lymphocytic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a chronic lymphocytic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Acute Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Recurrent Chronic Lymphocytic Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Recurrent Transformed Chronic Lymphocytic Leukemia
- Refractory Transformed Chronic Lymphocytic Leukemia
- Acute Myeloid Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.